Comparative Pharmacology
Head-to-head clinical analysis: CALQUENCE versus IBRUTINIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALQUENCE versus IBRUTINIB.
CALQUENCE vs IBRUTINIB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acalabrutinib is a selective, irreversible inhibitor of Bruton tyrosine kinase (BTK). BTK is a key signaling molecule in the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK activation results in pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Acalabrutinib and its active metabolite, acalabrutinib M27, form a covalent bond with the cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity and downstream signaling, thereby reducing malignant B-cell survival and proliferation.
Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in BTK's active site, leading to irreversible inhibition. BTK is essential for B-cell receptor signaling and survival of malignant B cells. Inhibition of BTK blocks pathways that promote B-cell proliferation, migration, and adhesion.
100 mg orally twice daily.
Adults: 560 mg orally once daily (4 capsules of 140 mg each) for mantle cell lymphoma; 420 mg once daily (3 capsules of 140 mg) for chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma, or chronic graft-versus-host disease.
Clinical Note
moderateIbrutinib + Digoxin
"Ibrutinib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateIbrutinib + Digitoxin
"Ibrutinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateIbrutinib + Deslanoside
"Ibrutinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateIbrutinib + Acetyldigitoxin
"Ibrutinib may decrease the cardiotoxic activities of Acetyldigitoxin."
None Documented
None Documented
Terminal elimination half-life is 8 hours at steady state, supporting twice-daily dosing.
Terminal half-life is approximately 4-6 hours, supporting twice-daily dosing for sustained BTK inhibition.
Fecal (77%), renal (15% as unchanged drug and metabolites).
Primarily fecal (80%) as metabolites, with renal excretion accounting for <10% (mostly as metabolites).
Category C
Category D/X
BTK Inhibitor
BTK Inhibitor